AstraZeneca plc stock (GB0009895292): Share price edges higher after 3.1% move and valuation focus

AstraZeneca plc shares are trading slightly higher on the London Stock Exchange after a 3.1% gain in the US market on 06/04/2026, while investors reassess valuation metrics and growth prospects following recent performance and sector developments.

AstraZeneca plc shares are drawing investor attention at the end of the week after a notable move in the US market and continued interest in the company’s valuation profile among large-cap pharmaceutical names.

According to GuruFocus, AstraZeneca’s American depositary shares closed at USD 181.80 on 06/04/2026, up 3.1% on the day, with the service highlighting a 52-week trading range between USD 120.20 and USD 186.40 as of that date, underscoring the stock’s strong run over the past year.GuruFocus as of 06/04/2026

In the United Kingdom, AstraZeneca is listed on the London Stock Exchange under the ticker AZN, with recent quote data from AJ Bell showing the shares changing hands around 13,752 pence on 06/05/2026, implying a daily gain of roughly 1.46% and reinforcing the home-market pricing reference for this FTSE 100 constituent.AJ Bell as of 06/05/2026

As of: 05/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: AstraZeneca
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: Cambridge, United Kingdom
• Core markets: Europe, United States, emerging markets
• Key revenue drivers: Oncology, cardiovascular, renal and metabolism therapies, vaccines and immune-related treatments
• Home exchange/listing venue: London Stock Exchange (AZN)
• Trading currency: GBP

AstraZeneca plc: core business model

AstraZeneca focuses on researching, developing and commercializing prescription medicines, with revenue primarily generated by patented treatments in oncology, cardiovascular and metabolic disease, respiratory and immunology, and vaccines and immune therapy franchises.

Valuation metrics and multiples for AstraZeneca plc

With AstraZeneca plc’s share price near the upper end of its 52-week range in the US market, valuation has again moved to the foreground for investors comparing the company with global pharmaceutical peers.

GuruFocus reported on 06/04/2026 that AstraZeneca’s American depositary shares at USD 181.80 implied a market capitalization in the large-cap range and corresponded to a price-to-earnings multiple in the low- to mid-20s on its trailing earnings, positioning the stock at a premium to several diversified pharma groups but in line with faster-growing innovators.GuruFocus as of 06/04/2026

The same GuruFocus analysis on 06/04/2026 noted a GF Score of 83 for AstraZeneca, based on factors including profitability, growth, financial strength, momentum and valuation, indicating that the company scores solidly across several fundamental dimensions even as the share price reflects high expectations for its pipeline and non-oncology growth drivers.GuruFocus as of 06/04/2026

Separately, an Investing.com report discussing Bernstein’s stance on AstraZeneca indicated in a recent analysis that the bank expects the company’s non-oncology business to account for around 65% of an anticipated 6% compound annual sales growth rate over the coming years, a perspective that can influence how investors think about AstraZeneca’s valuation relative to growth.Investing.com as of 05/2026

On the London Stock Exchange, where AstraZeneca is a key healthcare weight in the FTSE 100, the share price of around 13,752 pence on 06/05/2026 as reported by AJ Bell implies a similar valuation backdrop when translated into US dollars, supporting the view that both the UK and US lines trade consistently based on the company’s global earnings base and pipeline expectations.AJ Bell as of 06/05/2026

Conclusion

AstraZeneca plc’s share price performance around early June 2026, including a 3.1% rise in the US market on 06/04/2026 and firm trading on the London Stock Exchange, keeps the stock near the upper end of its 52-week range and in focus for investors tracking large-cap pharmaceuticals.

Valuation metrics such as a price-to-earnings multiple in the low- to mid-20s and a GF Score of 83 reported by GuruFocus on 06/04/2026 feed into the discussion about whether AstraZeneca’s earnings growth, particularly in non-oncology areas highlighted by Bernstein, sufficiently support the current market price.

How the company delivers on its pipeline, maintains momentum in both oncology and non-oncology franchises, and navigates competitive pressures will likely remain key factors for market participants assessing AstraZeneca plc’s risk-reward profile over the medium term.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.